KRAS and neoplasm: Contrary to previous reports on BRAFi-associated cSCCs in which somatic mutations in RAS were identified in 18–60% [12,13,14], in our murine tumors, activating mutations in the hotspot regions of Hras1, Kras and Nras, which might have contributed to tumor development, were not detected.